Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.65 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | FAP | Q12884 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15206677 | 1.00 | DPP4 (0.65) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL16433580 | 0.92 | DPP4 (0.55) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL14922003 | 0.87 | DPP4 (0.56) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL1289271 | 0.87 | DPP4 (0.56) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3254241 | 0.81 | DPP4 (0.64) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL3254233 | 0.81 | DPP4 (0.64) | DPP4DPP8DPP9DPP7ACE | |
| SCHEMBL5138244 | 0.79 | DPP4 (0.47) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL174489 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL17783 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE | |
| Sitagliptin SCHEMBL19520418 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP9DPP7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119082225-A | Sitagliptin Process for the preparation of intermediates | 浙江赞源生物技术有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-9181256-B2 | Salts of sitagliptin, process for the preparation and pharmaceutical composition therefore | LAURUS LABS PRIVATE LTD. (IN) | 2015-11-10 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20140073791-A1 | NOVEL SALTS OF SITAGLIPTIN, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2014-03-13 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-20100144613-A1 | Combined use of DPP-IV Inhibitors and Gastrin Compounds | WARATAH PHARMACEUTICALS, INC. (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20090054314-A1 | Combined use of DPP-IV inhibitors and gastrin compounds | WARATAH PHARMACEUTICALS INC. (CA) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073791-A1 | NOVEL SALTS OF SITAGLIPTIN, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 2/4885 |
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | DPP4 903/4885DPP8 2327/4885DPP9 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.